The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · cited 15×
“Gain-of-function mutations in the tyrosine kinase domain of the EGFR gene markedly increase sensitivity to EGFR TKIs.”
ResultInfluentialSelf-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 4×
“In third line, only erlotinib is registered for those who are EGFR TKI-naïve [32].”
BackgroundInfluentialMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · cited 3×
“During the course of the disease, 20%–30% of patients with metastatic NSCLC will develop brain metastases [46–48].”
BackgroundResultZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 4×
“A large open-label phase III trial compared oral treatment with crizotinib (250 mg, twice daily) with intravenous chemotherapy (either pemetrexed 500 mg/m(2) or docetaxel 75 mg/m(2)) in 347 patients with locally advanced or metastatic ALK-positive NSCLC who had received one prior platinum-based regimen [59].”
BackgroundResultInfluentialSelf-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationYu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“Consequently, relevant information is available on the most frequent mechanisms of resistance for EGFR inhibitors (T790M mutation, and less frequentlyMet amplification or HGF over-expression, small-cell transformation and others) or crizotinib (ALK mutation, ALK amplification and others such as EGFR mutation) [60–64].”
BackgroundScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citationCappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186 · cited 1×
“Two phase III randomised trials addressed the issue of ‘switch maintenance’ therapy with pemetrexed or erlotinib after four cycles of platinum-based chemotherapy [24, 25].”
BackgroundCiuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961 · cited 1×
“In a randomised phase III trial, which investigated afatinib versus placebo, pre-treatment with an EGFR TKI and chemotherapy failed to demonstrate a significant improvement of OS but revealed a significant improvement of RR and PFS in favour of afatinib [58].”
BackgroundWeickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · cited 1×
“EGFR or ALK inhibition in cases of oligometastatic progression, resulting in minimal toxicity and in months to years of disease control [65].”
BackgroundMazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Self-citationReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638
Self-citationPaz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610 · cited 1×
“0195, respectively) in the pemetrexed maintenance treated patients [26].”
BackgroundSelf-citationNSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · cited 1×
“Consequently, relevant information is available on the most frequent mechanisms of resistance for EGFR inhibitors (T790M mutation, and less frequentlyMet amplification or HGF over-expression, small-cell transformation and others) or crizotinib (ALK mutation, ALK amplification and others such as EGFR mutation) [60–64].”
BackgroundChaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1468 · Cited by 418
Welsh, J. W., Komaki, R., Amini, A., Munsell, M. F., Unger, W., Allen, P. K., Chang, J. Y., Wefel, J. S., McGovern, S. L., Garland, L. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1174 · Cited by 395
Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70385-0 · Cited by 374 · cited 1×
“The comparison of erlotinib with chemotherapy has only been addressed in patients who progressed during first-line therapy with no differences in PFS or OS [43].”
BackgroundScagliotti, G. V., Hirsh, V., Siena, S., Henry, D. H., Woll, P. J., Manegold, C., Solal-Celigny, P., Rodriguez, G., Krzakowski, M., Mehta, N. D., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aec2b · Cited by 335
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314 · cited 1×
“A meta-analysis showed superiority of platinum-based chemotherapy plus bevacizumab (an anti-VEGF antibody), when compared with chemotherapy alone [18].”
MethodZukin, M., Barrios, C. H., Rodrigues Pereira, J., De Albuquerque Ribeiro, R., de Mendonça Beato, C. A., do Nascimento, Y. N., Murad, A., Franke, F. A., Precivale, M., de Lima Araujo, L. H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1911 · Cited by 235
Lee, D. H., Park, K., Kim, J. H., Lee, J.-S., Shin, S. W., Kang, J.-H., Ahn, M.-J., Ahn, J. S., Suh, C., & Kim, S.-W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1903 · Cited by 179
Morabito, A., Gebbia, V., Di Maio, M., Cinieri, S., Viganò, M. G., Bianco, R., Barbera, S., Cavanna, L., De Marinis, F., Montesarchio, V., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.008 · Cited by 53
Self-citation
Cited by
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K. M., & Peters, S. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu199 · Cited by 679
Self-citationNon–Small Cell Lung Cancer, Version 6.2015
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478
Metadata
- Authors
- Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E. F., Syrigos, K., Stahel, R., Felip, E., Peters, S., Stahel, R., Felip, E., Peters, S., Kerr, K., Besse, B., Vansteenkiste, J., Eberhardt, W., Edelman, M., Mok, T., O'Byrne, K., Novello, S., Bubendorf, L., Marchetti, A., Baas, P., Reck, M., Syrigos, K., Paz-Ares, L., Smit, E. F., Meldgaard, P., Adjei, A., Nicolson, M., Crinò, L., Van Schil, P., Senan, S., Faivre-Finn, C., Rocco, G., Veronesi, G., Douillard, J.-Y., Lim, E., Dooms, C., Weder, W., De Ruysscher, D., Le Pechoux, C., De Leyn, P., & Westeel, V.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 25
- Issue
- 8
- Pages
- 1475-1484
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2130629599
- Cited by
- 244
- References
- 29
- FWCI
- 26.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.